GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
June 27, 2023 10:15 ET
|
GeoVax, Inc.
Spotlight Content on Pandemic Preparedness: Getting Ready for the Next “Disease X” ATLANTA, GA, June 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
May 31, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax to Participate in Upcoming Industry Meetings
May 25, 2023 09:00 ET
|
GeoVax, Inc.
Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
May 24, 2023 08:00 ET
|
GeoVax, Inc.
New and Unpublished Data from Phase 2 Open-Label Safety Study ofGEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings
May 15, 2023 09:00 ET
|
GeoVax, Inc.
Presentations to Include New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 ATLANTA, GA, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference
May 09, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
May 04, 2023 16:00 ET
|
GeoVax, Inc.
Cancer Gene Therapy Program and Next-Generation COVID-19 VaccineAdvancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30...
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
April 26, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious...
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
April 25, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and...
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
April 17, 2023 09:00 ET
|
GeoVax, Inc.
Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...